Skip to Content
UW Health SMPH
American Family Children's Hospital
SHARE TEXT
David F. Jarrard, MD close
ZEZIJdPU

David F. Jarrard, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment. Dr. Jarrard is also involved with surgical treatments for prostate cancer, such as the robotic prostatectomy.

Specialties

Urology

UW Health Clinics

UW Carbone Cancer Center
(608) 263-4757 | (800) 323-8942 | Map
UW Hospital and Clinics
(608) 263-4757 | (800) 323-8942 | Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)
Veterans Hospital - Wm. S. Middleton Memorial (secondary)

UW School of Medicine and Public Health

Department of Urology

Professional Certifications and Education

Board Certification Urology
Fellowship

Urologic Oncology, Johns Hopkins Hospital, Baltimore, MD


Residency University of Chicago Medical Center, Chicago, IL
Internship University of Chicago Medical Center, Chicago, IL
Medical School University of Virginia School of Medicine, Charlottesville, VA, 1989

Awards/Honors

Best Doctors® in America 2014

Best Doctors® in America 2013

Madison Magazine Top Docs 2012

Best Doctors® in America 2011


Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Procedures

Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.

Research

Dr. Jarrard has a joint appointment with the University of Wisconsin Carbone Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health to examine genetic and epigenetic alterations in prostate cancer.


PubMed Articles
Blute ML Jr Damaschke NA Jarrard DF . The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. Curr Opin Urol. 2015 Jan;25(1):83-8
[PubMed ID: 25405932]
Keil KP Abler LL Laporta J Altmann HM Yang B Jarrard DF Hernandez LL Vezina CM . Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development. Dev Biol. 2014 Dec 15;396(2):237-45
[PubMed ID: 25446526]
Jarrard DF Blute ML Jr Ritter MA . Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. J Clin Oncol. 2014 Dec 10;32(35):3926-9
[PubMed ID: 25332250]
Abel EJ Linder BJ Bauman TM Bauer RM Thompson RH Thapa P Devon ON Tarrell RF Frank I Jarrard DF Downs TM Boorjian SA . Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality? Eur Urol. 2014 Dec;66(6):1139-47
[PubMed ID: 25194909]
Damaschke NA Yang B Blute ML Jr Lin CP Huang W Jarrard DF . Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer. Neoplasia. 2014 Dec;16(12):1018-27
[PubMed ID: 25499215]
Abel EJ Bauman TM Weiker M Shi F Downs TM Jarrard DF Huang W . Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression. Hum Pathol. 2014 May;45(5):1092-9
[PubMed ID: 24746216]
Abel EJ Wong K Sado M Leverson GE Patel SR Downs TM Jarrard DF . Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy. JSLS. 2014 Apr-Jun;18(2):282-7
[PubMed ID: 24960494]
Yang B Wagner J Damaschke N Yao T Wuerzberger-Davis SM Lee MH Svaren J Miyamoto S Jarrard DF . A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation. PLoS One. 2014;9(2):e88052
[PubMed ID: 24558376]
Truong M Slezak JA Lin CP Iremashvili V Sado M Razmaria AA Leverson G Soloway MS Eggener SE Abel EJ Downs TM Jarrard DF . Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013 Nov 15;119(22):3992-4002
[PubMed ID: 24006289]
Yang B Wagner J Yao T Damaschke N Jarrard DF . Pyrosequencing for the rapid and efficient quantification of allele-specific expression. Epigenetics. 2013 Oct 1;8(10):1039-42
[PubMed ID: 23973940]
King AC Livermore A Laurila TA Huang W Jarrard DF . Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. Urol Oncol. 2013 Aug;31(6):739-43
[PubMed ID: 21816639]
Truong M Yang B Livermore A Wagner J Weeratunga P Huang W Dhir R Nelson J Lin DW Jarrard DF . Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol. 2013 Jun;189(6):2335-41
[PubMed ID: 23159584]
Gee J Bailey H Kim K Kolesar J Havighurst T Tutsch KD See W Cohen MB Street N Levan L Jarrard D Wilding G . Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jun;73(9):970-8
[PubMed ID: 23335089]
Yang B Bhusari S Kueck J Weeratunga P Wagner J Leverson G Huang W Jarrard DF . Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia. 2013 Apr;15(4):399-408
[PubMed ID: 23555185]
Slezak J Truong M Huang W Jarrard D . HP1γ expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy. BMC Cancer. 2013 Mar 23;13:148
[PubMed ID: 23522301]
Babaian K Truong M Cetnar J Cross DS Shi F Ritter MA Jarrard DF . Analysis of urological procedures in men who died from prostate cancer using a population-based approach. BJU Int. 2013 Mar;111(3 Pt B):E65-70
[PubMed ID: 23130676]
Ewald JA Desotelle JA Church DR Yang B Huang W Laurila TA Jarrard DF . Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo. Prostate. 2013 Mar;73(4):337-45
[PubMed ID: 22911222]
Truong M Yang B Wagner J Desotelle J Jarrard DF . Analysis of promoter non-CG methylation in prostate cancer. Epigenomics. 2013 Feb;5(1):65-71
[PubMed ID: 23414321]
Truong M Yang B Jarrard DF . Toward the detection of prostate cancer in urine: a critical analysis. J Urol. 2013 Feb;189(2):422-9
[PubMed ID: 23017522]
Ewald JA Jarrard DF . Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer. Transl Oncol. 2012 Aug;5(4):278-87
[PubMed ID: 22937180]